Wei Wang, Jing Zhang Xiao, Ke Zheng, Yi Pei
Department of Bone and Soft-Tissue Tumor Surgery, Cancer Hospital of China Medical UniversityShenyang 110042, Liaoning Province, PR China.
Department of Bone and Soft-Tissue Tumor Surgery, Liaoning Cancer Hospital & InstituteShenyang 110042, Liaoning Province, PR China.
Am J Cancer Res. 2017 Sep 1;7(9):1788-1803. eCollection 2017.
It is still a controversy whether the role of Sirtuin 7 (SIRT7) is an oncogene or a tumor suppressor gene in cancer as SIRT7 may have different functions in different types of cancer. Particularly, the specific roles of SIRT7 in the progression of osteosarcoma remain undiscovered. The main aim of this study is to identify the expression of SIRT7 in osteosarcoma and explore the biological functions of SIRT7 in regulating cellular processes of osteosarcoma cells. Here, we show that SIRT7 expression was significantly higher in osteosarcoma tissues and osteosarcoma cell lines than in non-tumor tissues and an immortalized normal cell line, respectively. Moreover, elevated SIRT7 levels in clinical samples indicate a poor prognosis of osteosarcoma patients. SIRT7 knockdown reduces proliferation, migration, invasion, tumor formation, and metastasis of osteosarcoma cells, while SIRT7 overexpression has the opposite effects. Mechanistically, SIRT7 down regulates H3K18ac expression and decreases H3K18ac binding to the promoter region of CDC4, leading to the inhibition of CDC4 transcription. Furthermore, the silencing of CDC4 partially rescued SIRT7 knockdown-mediated inhibitory effects on proliferation, migration, and invasion of osteosarcoma cells. In summary, our results show that SIRT7 promotes proliferation, migration, and invasion of osteosarcoma cells through targeting CDC4, suggesting a potential therapeutic target for SIRT7 based therapy for osteosarcoma.
沉默调节蛋白7(SIRT7)在癌症中究竟是癌基因还是肿瘤抑制基因仍存在争议,因为SIRT7在不同类型的癌症中可能具有不同的功能。特别是,SIRT7在骨肉瘤进展中的具体作用仍未被发现。本研究的主要目的是确定SIRT7在骨肉瘤中的表达,并探讨SIRT7在调节骨肉瘤细胞生物学过程中的生物学功能。在此,我们发现骨肉瘤组织和骨肉瘤细胞系中SIRT7的表达分别显著高于非肿瘤组织和永生化正常细胞系。此外,临床样本中SIRT7水平升高表明骨肉瘤患者预后不良。敲低SIRT7可降低骨肉瘤细胞的增殖、迁移、侵袭、肿瘤形成和转移,而SIRT7过表达则具有相反的作用。机制上,SIRT7下调H3K18ac表达并减少H3K18ac与CDC4启动子区域的结合,导致CDC4转录受到抑制。此外,沉默CDC4部分挽救了SIRT7敲低介导的对骨肉瘤细胞增殖、迁移和侵袭的抑制作用。总之,我们的结果表明,SIRT7通过靶向CDC4促进骨肉瘤细胞的增殖、迁移和侵袭,提示基于SIRT7的骨肉瘤治疗具有潜在的治疗靶点。